Patients with locally advanced head and neck squamous cell carcinoma who showed significant tumor shrinkage after receiving neoadjuvant immunochemotherapy achieved a 90% disease-free survival rate at two years while undergoing less extensive surgery, according to a study published in Clinical Cancer Research.
Reduced-Volume Surgery After Immunochemotherapy Shows High Survival Rates
More than 60% of head and neck squamous cell carcinoma (HNSCC) patients face diagnosis at a locally advanced stage, carrying high risks of recurrence and metastasis. Traditional treatment usually involves radical surgery followed by radiotherapy, or definitive chemoradiotherapy without surgery. According to Dr. Kunyu Yang, director of the Union Hospital Cancer Center at Tongji Medical College and Huazhong University of Science and Technology, radical surgery frequently causes facial disfigurement and organ dysfunction.
To evaluate a less destructive approach, Yang and his research team administered three cycles of neoadjuvant immunochemotherapy (ICT) to 52 patients with HPV-negative, locally advanced resectable HNSCC. Out of the 47 patients who completed the therapy and proceeded to surgery, 42 patients—representing 90% of the surgical group—experienced tumor shrinkage of 50% or greater and received reduced-volume surgery. Findings published in the American Association for Cancer Research journal show that 90% of these patients remained free of recurrence, metastasis, or death at the two-year mark.
Complete Laryngeal Function Preservation Achieved
Preserving vital swallowing and speech functions remains a primary challenge in head and neck cancer treatment. While chemoradiotherapy can spare organs like the larynx and pharynx, long-term complications often include voice loss, severe dysphagia, and feeding tube dependence. By shrinking tumors prior to operation through ICT, surgeons can spare healthy surrounding structures.
In the Clinical Cancer Research study, laryngeal function was preserved entirely in all 39 patients who presented with laryngeal or hypopharyngeal cancer and subsequently underwent reduced-volume surgery. This outcome highlights how targeted neoadjuvant drug therapy before surgical intervention can protect critical physical functions without sacrificing oncological control.
PD-L1 Expression as a Predictive Biomarker
The study also evaluated the potential of PD-L1 expression to predict patient response to neoadjuvant immunochemotherapy. Higher PD-L1 Combined Positive Score (CPS) values correlated positively with improved pathological complete response rates. Specifically, 65% of patients with a high PD-L1 CPS exceeding 20 achieved a pathological complete response, compared to 28% of patients with a CPS between 1 and 19, and 14% of those with lower scores.
Despite these promising results, researchers noted several limitations. The study relied on a single-arm design with a relatively small sample size consisting predominantly of laryngeal and hypopharyngeal cancers. Yang emphasized that while the findings provide a strong rationale for further investigation, they are not yet sufficient to alter current clinical standards of care.
Did you know? Head and neck cancers most commonly develop in the squamous cells lining the mucosal surfaces of the oral cavity, pharynx, and larynx, with HPV-negative cases traditionally associated with particularly poor outcomes.
Frequently Asked Questions
What is neoadjuvant immunochemotherapy?
Neoadjuvant immunochemotherapy involves administering a combination of immunotherapy and chemotherapy drugs before primary treatment, such as surgery, to shrink tumors and improve overall outcomes.
What is reduced-volume surgery?
Reduced-volume surgery is a targeted surgical procedure that removes residual tumor tissue while minimizing the impact on nearby healthy structures and organs.
Why is organ preservation important in head and neck cancer?
Treatments like radical surgery and standard chemoradiotherapy can lead to severe long-term side effects, including facial disfigurement, voice loss, and feeding tube dependence.
Explore More: Share your thoughts on this study in the comments below, or subscribe to our newsletter for the latest updates in oncology research and clinical trials.
Keep reading